US 12,186,575 B2
Method and apparatus for oncomagnetic treatment
Santosh Anand Helekar, Sugar Land, TX (US); David Stuart Baskin, Houston, TX (US); Martyn Alun Sharpe, Houston, TX (US); and Kumar Pichumani, Sugar Land, TX (US)
Assigned to THE METHODIST HOSPITAL, Houston, TX (US)
Appl. No. 17/293,461
Filed by THE METHODIST HOSPITAL, Houston, TX (US)
PCT Filed Nov. 13, 2019, PCT No. PCT/US2019/061131
§ 371(c)(1), (2) Date May 12, 2021,
PCT Pub. No. WO2020/102312, PCT Pub. Date May 22, 2020.
Claims priority of provisional application 62/901,128, filed on Sep. 16, 2019.
Claims priority of provisional application 62/760,779, filed on Nov. 13, 2018.
Prior Publication US 2021/0402199 A1, Dec. 30, 2021
Int. Cl. A61N 2/00 (2006.01); A61K 31/19 (2006.01); A61K 31/20 (2006.01); A61N 2/12 (2006.01)
CPC A61N 2/002 (2013.01) [A61K 31/19 (2013.01); A61K 31/20 (2013.01); A61N 2/004 (2013.01); A61N 2/12 (2013.01)] 17 Claims
OG exemplary drawing
 
1. A method for disrupting mitochondrial function in cells, the method comprising:
causing, by controlling hardware, a magnet to generate an oscillating magnetic field (OMF), including ramping a frequency of the OMF to a peak frequency of between 250 HZ and 350 Hz, over a period of 75 ms to 100 ms; and
applying the oscillating magnetic field to a volume of tissue including cells with a mitochondrial impairment to trigger apoptosis in the cells with the mitochondrial impairment.